NuVasive Gains Clearance for Expanded Use of Attrax Putty

NuVasive received FDA 510(k) clearance for expanded indications of use for Attrax® Putty with its thoracolumbar interbody portfolio for spine surgery. Attrax Putty is reportedly the first synthetic biologic to receive indications for use in interbody fusion of the thoracolumbar spine.

Attrax Putty is a synthetic, bioactive and osteoconductive...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0